Cosmetic Regulation Update's Link With OTC Drug User Fees Clear At Hearing
This article was originally published in The Rose Sheet
Executive Summary
Members of the House Health Subcommittee suggest their support for potential OTC monograph reform legislation depends on including provisions that would add substantial details to FDA's oversight of cosmetics manufacturers and a related user fee program.
You may also be interested in...
OTC Monograph Reform Momentum Carries Potential Exclusivity Snag
Support was unanimous during House Health Subcommittee markup for draft legislation on streamlining FDA's monograph system by eliminating public rulemakings from the process and allowing the agency to make decisions with administrative orders. Two-year exclusivity for some products didn't go over so well.
Rose Report Podcast – September 2017
Rose Sheet’s editorial team counts down top news items in the cosmetics and dietary supplement sectors over the past month, including possible cosmetics regulatory convergence under a renegotiated NAFTA, the FTC’s first enforcement action against social media influencers, FDA movement to develop a list of “old dietary ingredients” pre-dating DSHEA, and more.
No Authorization For OTC Monograph Reform And User Fees, But Webinar Goes On
FDA’s Aug. 23 webinar will update industry stakeholders on progress to modernize its OTC monograph program, but without user fee legislation, new performance goals will not take effect; stakeholders hold out hope a standalone OTC user fee bill could still progress in Congress.